Richardson PG, Hungria VTM, Yoon S-S, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016;127(6):713-721.

On pages 716 and 717 in the 11 February 2016 issue, the median duration of treatment in the control arm for patients who received ≥2 prior regimens including bortezomib and an immunomodulatory drug was incorrectly listed as 4.7 months. The correct median duration of treatment is 4.8 months. The error occurs on line 2 of page 716 and in the last line of the first full paragraph on page 717; on page 717, “median duration of treatment and median PFS were both 4.7 months” should read “median duration of treatment and median PFS were 4.8 and 4.7 months, respectively.”

The error has been corrected in the online version, which now differs from the print version.